NASDAQ$SHC
Sotera Health Company · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Sotera Health Company reported consolidated net revenues of $294.3 million and net income of $8.0 million for the second quarter ended June 30, 2025.
Sotera Health delivered revenue growth of 6.4% year-over-year in Q2 2025, driven by strength in the Sterigenics segment and favorable pricing. The company recorded net income of $8.0 million despite $34.0 million in Illinois EO litigation settlement charges. Adjusted EBITDA rose 9.8% to $150.7 million, reflecting solid operational performance across sterilization and lab services.
- Total net revenues reached $294.3 million, up 6.4% from Q2 2024, with service revenues increasing 8.2%.
- Sterigenics segment income grew 11.3% to $107.7 million on higher volumes and pricing.
- Net income was $8.0 million after $34.0 million EO litigation settlement expense.
- Adjusted EBITDA increased 9.8% to $150.7 million with segment income margins expanding in Sterigenics and Nelson Labs.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$294M
Revenue by segment
Sotera Health · $294M total across 3 segments · Q2 2025
- Sterigenics$195M—66.2%
- Nelson Labs$57.1M—19.4%
- Nordion$42.4M—14.4%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro